Sign inCreate account

Report workspace

Add to folder
NCT02598661ACTIVE_NOT_RECRUITINGanonymous

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Sponsor

Source record

Geron Corporation

Phase

Source record

Phase 2/3

Modality

AI-normalized

small molecule

Target

AI-normalized

Imetelstat sodium targets telomerase, inhibiting its activity to induce apoptosis in malignant cells, particularly in myelodysplastic syndromes (MDS).

Indication / condition

AI-normalized

Myelodysplastic Syndromes

Intervention

Source record

Imetelstat Sodium, Placebo

Source & freshness

Source record

NCT ID

NCT02598661

Original source

ClinicalTrials.gov

Source last updated

Jan 05, 2026

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02598661

Title

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Sponsor

Geron Corporation

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2/3

Condition raw

Myelodysplastic Syndromes

Condition normalized

Myelodysplastic Syndromes

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Imetelstat sodium targets telomerase, inhibiting its activity to induce apoptosis in malignant cells, particularly in myelodysplastic syndromes (MDS).

Target normalized

Imetelstat sodium targets telomerase, inhibiting its activity to induce apoptosis in malignant cells, particularly in myelodysplastic syndromes (MDS).

Interventions

Imetelstat Sodium, Placebo

Public preview

Source record

Imetelstat sodium, developed by Geron Corporation, is positioned to address a significant unmet need in the treatment of transfusion-dependent patients with low or intermediate-1 risk MDS who are relapsed/refractory to erythropoiesis-stimulating agents (ESAs). The market for MDS therapies is growing, with increasing demand for effective treatments that can improve transfusion independence and overall survival. Competitive landscape includes hypomethylating agents and other novel therapies, but imetelstat's unique mechanism may provide a differentiated offering. Diligence should focus on the robustness of clinical data, potential regulatory pathways, and the landscape of ongoing and upcoming clinical trials in MDS.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT02598661

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2/3

Sponsor

Geron Corporation

Executive brief

Investment-Ready Snapshot

Imetelstat sodium, developed by Geron Corporation, is positioned to address a significant unmet need in the treatment of transfusion-dependent patients with low or intermediate-1 risk MDS who are relapsed/refractory to erythropoiesis-stimulating agents (ESAs). The market for MDS therapies is growing, with increasing demand for effective treatments that can improve transfusion independence and overall survival. Competitive landscape includes hypomethylating agents and other novel therapies, but imetelstat's unique mechanism may provide a differentiated offering. Diligence should focus on the robustness of clinical data, potential regulatory pathways, and the landscape of ongoing and upcoming clinical trials in MDS.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 05, 2026
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02598661

Indication

Myelodysplastic Syndromes

Modality

small molecule

Target

Imetelstat sodium targets telomerase, inhibiting its activity to induce apoptosis in malignant cells, particularly in myelodysplastic syndromes (MDS).

Intervention

Imetelstat Sodium, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.